Advancing the Standard of Care in Inflammatory Diseases Through Innovation

SL-325 is the first clinical stage monoclonal antibody targeting DR3, the receptor for TL1A, which has potential to achieve best-in-class remission rates in IBD and beyond.

Our Pipeline
3D rendering of SL-325 antibody3D rendering of SL-325 antibody
3D rendering of SL-325 antibody

Establishing DR3 as a Foundational Target in IBD and Beyond

Shattuck is developing a potentially first-in-class DR3 blocking antibody for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases. Targeting immune receptors, like DR3, may provide superior efficacy than targeting immune ligands such as TL1A. In addition, DR3 blocking antibodies are not expected to cause immune complex formation and thus may have a superior immunogenicity profile in comparison to TL1A blocking antibodies.

Our Science
3D molecular rendering of the DR3 receptor
Leads
Indications
Preclinical
IND-Enabling
clinical
Phase 2
Leads
SL-325
Indications
IBD
Phase 1
Leads
SL-425
Extended Half-Life
Indications
IBD
IND-Enabling
Leads
Bispecifics
Indications
Autoimmune
Preclinical

Our Pipeline

Shattuck’s lead DR3 blocking antibody, SL-325, demonstrates superior inhibition and efficacy in preclinical assays over therapies targeting TL1A. SL-325 harnesses the power of high affinity, epitope specificity and critical Fc-silencing to block TL1A from engaging DR3 expressed on multiple immune cells that drive inflammation.

Our Pipeline

Join Us

In our relentless desire to improve the lives of patients

Explore Careers
Scientist looking through a microscope in a laboratory
Researchers working together in a laboratory

Our Team

Meet the Innovators Guiding the Mission

Meet Our Team
Taylor H. Schreiber, MD, PhDAbhinav A. Shukla, PhDThomas Lampkin, PharmDLini Pandite, MD, MBASuresh de Silva, PhDAmy Franke, MBE
Taylor H. Schreiber, MD, PhDAbhinav A. Shukla, PhDThomas Lampkin, PharmDLini Pandite, MD, MBASuresh de Silva, PhDAmy Franke, MBE
Taylor H. Schreiber, MD, PhDCasi DeYoung, MBAStephen Stout, JD, PhDMichael Choi, MDAndrew R. Neill, MBAKelli Collin, MBA
Taylor H. Schreiber, MD, PhDCasi DeYoung, MBAStephen Stout, JD, PhDMichael Choi, MDAndrew R. Neill, MBAKelli Collin, MBA

Locations

Shattuck has R&D facilities in Durham, North Carolina and a Corporate office in Austin, Texas.

Contact Us
Exterior of Shattuck Labs R&D office building in Durham, North Carolina
Exterior of Shattuck Labs corporate office building in Austin, Texas

News & Events

October 2, 2025

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel.

October 2, 2025

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel.

October 2, 2025

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel.

October 2, 2025

Berlin, Germany

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

October 2, 2025

Berlin, Germany

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

October 2, 2025

Berlin, Germany

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

View All